Table 2.

Characteristics of patients with HCC

Number nodules	Maximum diameter, cm	Portal vein thrombus	Extrahepatic spread	BCLC stage	Surveillance AFP level	Surveillance ultrasound results
1	3.2	None	No	A	54.3	−
1	2.5	None	No	D^a	22.9	+
1	2.5	None	No	A	11.3	+
7	3.2	None	No	B	48.4	Not done
1	1.4	None	No	A	6.4	Not done
1	1.8	None	No	D^a	3.8	−^b
2	2.8	Bland	No	A	2.3	+
1	2.3	None	No	A	73.0	Not done
4	2.4	Bland	No	B	25.8	−
2	1.1	None	No	A	16.4	Not done
1	3	None	No	D^a	13.6	−
1	2.2	None	No	D^a	27.7	+
1	2.1	None	No	A	37.8	Not done
2	2.8	None	No	A	23.5	−
2	2.3	None	No	A	5.3	+
2	3.8	None	No	B	4.3	+
1	1.5	None	No	D^a	42.2	−
1	2.8	None	No	A	2.2	+
3	2.2	Bland	No	A	1,442.9	+
2	13.7	Tumor	Yes	C	635	Not done
1	2.1	None	No	A	42.1	Not done
1	3.2	None	No	A	5.1	+
1	2.0	None	No	A	69.7	Not done
1	1.7	None	No	A	2.4	−^b
2	3.2	None	No	B	35.4	+
3	4.2	Tumor	Yes	C	30.0	−
3	1.8	None	No	A	33.2	+
4	1.4	None	No	D^a	3.0	+
1	2.1	None	No	A	11.1	−
1	3.1	None	No	D^a	2.6	−^b
2	3.6	None	No	B	404.9	+
1	2.6	None	No	A	20.0	+
2	1.4	Tumor	Yes	C	3.1	+
1	3.2	None	No	A	24.0	+
2	4.6	None	No	B	277.7	Not done
2	0.6	None	No	D^a	2.2	−^b
3	1.5	None	No	A	15.7	−
2	2.0	None	No	A	203.9	−
2	5.2	None	No	B	36.8	Not done
1	1.7	None	No	A	10.1	+
1	1.7	None	No	A	3.2	+

NOTE: Usual practice was to conduct triple-phase CT or MRI in patients with an increasing AFP level greater than 20 ng/mL.

↵^aTumors were staged as BCLC D given underlying Child C cirrhosis at the time of diagnosis
↵^bHCC was incidentally diagnosed at time of liver transplantation or when cross-sectional imaging was conducted to evaluate gastrointestinal symptoms (abdominal pain, nausea, and jaundice).